Ethical considerations in cardiovascular prevention

Fundamental and Clinical Pharmacology

Volumn 23, Issue 6, 2009, Pages 669-673

  Follath, F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular diseases; Medical ethics; Prophylaxis

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; ESTROGEN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PROGESTERONE;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; ECONOMIC ASPECT; GROUPS BY AGE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; MEDICAL ETHICS; MORTALITY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT DURATION; TREATMENT REFUSAL; UTERUS CANCER; VENOUS THROMBOEMBOLISM;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; ETHICS, MEDICAL; HUMANS; HYPOGLYCEMIC AGENTS; INFORMED CONSENT; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SECONDARY PREVENTION;

EID: 70449473550     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00695.x     Document Type: Review

References (27)

1. Velagaleti R.S., Pencina M.J., Murabito J.M., et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation (2008) 118 2057 2062.
2. Fourth Joint Task Force of the European Society of Cardiology and other Societies. European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. (2007) 28 2375 2414.
3. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet (2005) 366 1267 1278.
4. Staessen J.A., Wang J.-G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 358 1305 1315.
5. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensine-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) 342 145 153.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet (1994) 344 1383 1399.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit. Med. J. (2002) 324 71 86.
8. Goff D.C. Jr., Gerstein H.C., Ginsberg H.N., et al. Prevention of cardiovascular disease in persons with type two diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am. J. Cardiol. (2007) 99 4i 20i.
9. Yusuf S. Two decades of progress in preventing vascular disease. Lancet (2002) 360 2 3.
10. Roussow J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results fro the Womens' Health Initiative randomised controlled trial. J. Am. Med. Assoc. (2002) 288 321 333.
11. Lokkegaard E., Andreasen A.H., Jacobsen R.K., et al. Hormone therapy and risk of myocardial infarction: an national register study. Eur. Heart J. (2008) 29 2660 2668.
12. Alsheikh-Ali A.A., Maddakuri P.V., Han H., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J. Am. Coll. Cardiol. (2007) 50 409 418.
13. Rossebo A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. (2008) 359 1343 1356.
14. Dale K.M., Coleman C.I., Henyan N.N., et al. Satines and cancer risk. A meta-analysis. JAMA 2008) 295 74 80.
15. Karp I., Behlouli H., LeLorier J., et al. Statins and cancer risk. Am. J. Med. (2008) 121 302 309.
16. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. (2008) 358 2545 2555.
17. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. (2008) 358 2560 2572.
18. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356 2457 2471. (Pubitemid 46919772)
19. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. (2008) 358 1547 1559.
20. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360 1623 1630.
21. Ridker P.M., Cook N.R., Lee I.-M., et al. A randomised trial of low dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. (2005) 352 1293 1304.
22. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA (2006) 295 306 313.
23. Julin T., Jönsson B.A.G., Höglund P. Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. Eur. J. Heart. Fail. (2008) 10 892 898.
24. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. (2003) 326 1 6.
25. Gaziano T., Opie L.H., Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006) 368 679 686.
26. Sleight P., Pouleur H., Zannad F. Benefits, challenges, and registerability of the polypill. Eur. Heart. J. (2006) 27 1651 1656.
27. Neumann P.J., Rosen A.B., Weinstein M.C. Medicare and cost-effectiveness anlysis. N. Engl. J. Med. (2005) 353 1516 1522.